Hunan Cancer Hospital
湖南省肿瘤医院
Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Hunan Cancer Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌53 papers led2 open trials led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led1 open trial led
- Hepatocellular carcinoma肝细胞癌16 papers led1 open trial led
- Stomach cancer胃癌25 papers led2 open trials led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤8 papers led
- Ewing sarcoma尤文肉瘤1 paper led
- Multiple myeloma多发性骨髓瘤0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
- IgA nephropathyIgA 肾病1 paper led
Not listed for: Hepatoblastoma, Retinoblastoma, Gastrointestinal stromal tumour, Neuroblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 53 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 2.2%.
6 hospitals in Changsha for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 12
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06788002
Age 18 years to 70 years (registered criteria)
Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha
- RecruitingSequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06321939
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingPD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07235319
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou, Hangzhou, Nanning
- RecruitingIndividualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07661771
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan
- RecruitingProphylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07796789
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou
- RecruitingQL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06749899
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan
- RecruitingA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Registry
- NCT07258979
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen
- RecruitingPrevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07311772
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai
- RecruitingReduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328841
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai
- Recruiting40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328854
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai
- RecruitingReduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06239727
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Phase
- Phase 1
- Started
- 2021-11
- Registry
- NCT05194982
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led53
- CircCDYL promotes glycolysis to drive the progression of nasopharyngeal carcinoma.
- circSETD3 confers radiotherapy resistance in nasopharyngeal carcinoma by attenuating ER stress-induced autophagy and apoptosis via PDIA6 upregulation.
- Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose- painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial.
- Early prediction of progression-free survival of patients with locally advanced nasopharyngeal carcinoma using multi-parametric MRI radiomics.
- Diagnostic value of BNLF2b antibody, dual-antibody testing and Epstein-Barr virus DNA in nasopharyngeal carcinoma: a prospective cohort study in Hunan Province, China.
- Combining decitabine with radiotherapy to enhance nasopharyngeal carcinoma radiosensitivity via the TFAP2C-OTUD1-SLC25A11 axis.
- circADARB1 enhances ZEB1 expression in an m6A-dependent manner to promote the invasion and migration of nasopharyngeal carcinoma.
- CD38 inhibits ferroptosis to promote radiotherapy resistance in nasopharyngeal carcinoma by competitively binding to TRIM21 to stabilize SLC7A11 protein.
- Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation.
- CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR-15b-5p and miR-7-1-3p processing in nasopharyngeal carcinoma.
- O-GlcNAc-modified HOXA9 suppresses ferroptosis via promoting UBR5-mediated SIRT6 degradation in nasopharyngeal carcinoma.
- m6A modification-dependent upregulation of WNT2 facilitates M2-like macrophage polarization and perpetuates malignant progression of nasopharyngeal carcinoma.
- Deep learning Radiopathomics based on pretreatment MRI and whole slide images for predicting overall survival in locally advanced nasopharyngeal carcinoma.
- circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1/Hippo signaling pathway.
- Nanocarriers Targeting Circular RNA ADARB1 Boost Radiosensitivity of Nasopharyngeal Carcinoma through Synergically Promoting Ferroptosis.
- Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy.
- CircBRD7 attenuates tumor growth and metastasis in nasopharyngeal carcinoma via epigenetic activation of its host gene.
- Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2.
- A specific super-enhancer actuated by berberine regulates EGFR-mediated RAS-RAF1-MEK1/2-ERK1/2 pathway to induce nasopharyngeal carcinoma autophagy.
- Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein.
- METTL14 promotes lipid metabolism reprogramming and sustains nasopharyngeal carcinoma progression via enhancing m6A modification of ANKRD22 mRNA.
- BRD7 enhances the radiosensitivity of nasopharyngeal carcinoma cells by negatively regulating USP5/METTL3 axis-mediated homologous recombination repair.
- FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma.
- Integrative radiopathomics model for predicting progression-free survival in patients with nonmetastatic nasopharyngeal carcinoma.
- CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair.
- Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
- Evolution of radiation-induced temporal lobe injury after intensity-modulated radiation therapy in nasopharyngeal carcinoma: a large cohort retrospective study.
- Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities.
- LPLUNC1 reduces glycolysis in nasopharyngeal carcinoma cells through the PHB1-p53/c-Myc axis.
- USP7 inhibits the progression of nasopharyngeal carcinoma via promoting SPLUNC1-mediated M1 macrophage polarization through TRIM24.
- JUN-induced super-enhancer RNA forms R-loop to promote nasopharyngeal carcinoma metastasis.
- BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma.
- Circular RNA circRILPL1 promotes nasopharyngeal carcinoma malignant progression by activating the Hippo-YAP signaling pathway.
- ACSL4 promotes ferroptosis and M1 macrophage polarization to regulate the tumorigenesis of nasopharyngeal carcinoma.
- Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma.
- Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.
- Epstein-Barr virus microRNA miR-BART2-5p accelerates nasopharyngeal carcinoma metastasis by suppressing RNase Ⅲ endonuclease DICER1.
- A novel oncogenic seRNA promotes nasopharyngeal carcinoma metastasis.
- MRI-based radiomics nomogram for predicting temporal lobe injury after radiotherapy in nasopharyngeal carcinoma.
- Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Tr
- SPLUNC1 regulates LPS-induced progression of nasopharyngeal carcinoma and proliferation of myeloid-derived suppressor cells.
- Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop.
- Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop.
- EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.
- Characteristics of locoregional extension of unilateral nasopharyngeal carcinoma and suggestions for clinical target volume delineation.
- Circular RNA circCCNB1 inhibits the migration and invasion of nasopharyngeal carcinoma through binding and stabilizing TJP1 mRNA.
- Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance.
- Cyclophilin A binds to AKT1 and facilitates the tumorigenicity of Epstein-Barr virus by mediating the activation of AKT/mTOR/NF-κB positive feedback loop.
- Failure patterns and prognostic factors for cervical node-negative nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
- Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1.
- Bioinformatics Analysis of the Signaling Pathways and Genes of Gossypol Induce Death of Nasopharyngeal Carcinoma Cells.
- Effects of Cognitive Behavioral Therapy for Depression and Anxiety, Response Rates and Adverse Events in Patients with Locoregional Advanced Nasopharyngeal Carcinoma.
- Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status26
- LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
- Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma
- Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
- PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
- Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
- Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
- Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
- A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
- To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
- Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
- Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
More papers found outside PubMed (not counted)54
- 1390P Updated long term efficacy results of phase II study for becotatug vedotin combined with pucotenlimab in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
- 1423P Real-world evidence of neoadjuvant immunotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis
- 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
- A Transcriptome Sequencing Analysis on Berberine-mediated Gene Expression in Nasopharyngeal Carcinoma cells
- Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
- Aptamers Associated with Nasopharyngeal Carcinoma Metastasis
- Association between high HBV-DNA viral load and liver metastasis risk in patients with nasopharyngeal carcinoma
- Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.
- LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv
- Potential Collaborative Markers for Nasopharyngeal Carcinoma Diagnosis and Therapy: AGR2 and AKR1B10
- Serum tsRNA profile of Nasopharyngeal Carcinoma Patients with Various Chinese Medicine Syndrome
- Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
- Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car
- WITHDRAWN: 1383P Preliminary efficacy analysis of cetuximab-enhanced induction chemotherapy for locally advanced refractory nasopharyngeal carcinoma
- 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
- Abstract CT113: A dose-exploring, randomized, open-label, Phase I study for toripalimab subcutaneous injection in patients with advanced nasopharyngeal carcinoma
- Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study
- Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.
- Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).
- Long Term Effects of Cognitive Behavioral Therapy on Late Toxicities, Depressive and Anxiety Symptoms in Patients with Locoregional Advanced Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy: A Randomized, Controlled Clinical Trial
- Long Term Outcomes and Late Toxicity of Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting Radiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled Clinical Trial
- Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.
- Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.
- RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA
- Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomiz
- 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma
- Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.
- Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.
- Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
- Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1
- Distribution Pattern of Metastatic Lymph Nodes in 870 Cases of Nasopharyngeal Carcinoma: A Clue for Individualized Elective Prophylactic Neck Irradiation
- Distribution pattern of metastatic lymph nodes in 870 cases of nasopharyngeal carcinoma: A clue for individualized elective prophylactic neck irradiation.
- Dose Painting Radiotherapy Guided by Diffusion-Weighted Magnetic Resonance vs. 18F-FDG-PET/CT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled Clinical Trial
- Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- WITHDRAWN: Targeting the PLUNC-NLRP3 inflammasome axis could inhibit nasopharyngeal carcinoma lung metastasis
- A Randomized Controlled Trial of Cognitive Behavior Therapy to Reduce Oral Mucositis in Patients with Locoregional Advanced Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy
- A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
- Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca
- Four-year result of diffusion-weighted, MRI-guided, dose-painting radiotherapy following induction chemotherapy in patients with locally advanced recurrent nasopharyngeal carcinoma: A randomized controlled trial.
- Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.
- PRMT5 regulates the NAD-SIRT1-p53 signal axis by affecting the methylation of CD38 at R58 to promote malignant tumor cell proliferation
- Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.
- Serum Level of Tumor-Specific Growth Factor in Patients with Cervical Cancer and Its Potential Prognostic Role
- 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
- 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
- A Randomized Controlled Trial of Cognitive Behavior Therapy for Reducing Anxiety and Depressive Symptoms in Patients With Locally Recurrent Nasopharyngeal Carcinoma Receiving Reirradiation
- A Randomized Controlled Trial of Reirradiation Using Diffusion-Weighted MRI Guided Dose-Painting vs. CT-Based Radiotherapy for Locally Recurrent T3 to T4 Nasopharyngeal Carcinoma
- A randomized controlled trial of cognitive behavior therapy for reducing anxiety and depressive symptoms in patients with locoregional advanced nasopharyngeal carcinoma.
- A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.
- Efficacy of Concurrent Chemoradiotherapy In Subgroups of Stage III Nasopharyngeal Carcinoma: An Analysis Based On 10-Year Follow-Up
- JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
- [Retracted] MicroRNA‑19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 2
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
3 hospitals in Changsha for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07090499
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingChemoradiotherapy in Unresectable Esophageal Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-10
- Registry
- NCT04278287
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led7
- MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction.
- Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
- High FN1 expression is associated with poor survival in esophageal squamous cell carcinoma.
- Histone Demethylase GASC1 Inhibitor Targeted GASC1 Gene to Inhibit the Malignant Transformation of Esophageal Cancer through the NOTCH-MAPK Signaling Pathway.
- OPN Promotes Cell Proliferation and Invasion through NF-κB in Human Esophageal Squamous Cell Carcinoma.
- Network analysis of genes associated with esophageal squamous cell carcinoma progression.
- Comparison of tumor-associated and nontumor-associated esophageal mucosa microbiota in patients with esophageal squamous cell carcinoma.
All its trials on ClinicalTrials.gov, any status24
- A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
- Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Chemoradiotherapy in Unresectable Esophageal Cancer
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
- Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial
More papers found outside PubMed (not counted)14
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study
- The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.
- A phase I/II study of C019199 in combination with sintilimab in advanced malignancy.
- AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.
- Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study
- Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
- Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t
- “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study
- A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.
- O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
- Comprehensive analysis based on methylation microarrays and single-cell transcriptomics in esophageal squamous cell carcinoma
- ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 16 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
6 hospitals in Changsha for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingCadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06406634
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06742892
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingPhase 2 Study of WGI-0301 for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06309485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
- RecruitingA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06371157
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Hangzhou, Nanjing, Zhengzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Registry
- NCT05652920
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led16
- Prognostic model construction and immune microenvironment analysis of pyroptosis-related genes in hepatocellular carcinoma based on single-cell RNA sequencing.
- Exploring the heterogeneity of cancer-related fatigue in advanced hepatocellular carcinoma patients via latent profiles and influencing factors.
- Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma.
- Exosomal PDL1 Suppresses the Anticancer Activity of CD8+ T Cells in Hepatocellular Carcinoma.
- The survival prediction analysis and preliminary study of the biological function of YEATS2 in hepatocellular carcinoma.
- let-7g sensitized liver cancer cells to 5-fluorouracil by downregulating ABCC10 expression.
- A multi-omic analysis reveals that Gamabufotalin exerts anti-hepatocellular carcinoma effects by regulating amino acid metabolism through targeting STAMBPL1.
- E2F1-mediated KDM4A-AS1 up-regulation promotes EMT of hepatocellular carcinoma cells by recruiting ILF3 to stabilize AURKA mRNA.
- SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
- Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score.
- Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
- Diagnostic accuracy of circulating exosomal circRNAs in malignances: A meta-analysis and systematic review.
- Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
- Identification of key snoRNAs serves as biomarkers for hepatocellular carcinoma by bioinformatics methods.
- Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features.
- Differential Analysis of IncRNAs and mRNAs Expression in HCC and the Predictive Value of lncRNAs.
All its trials on ClinicalTrials.gov, any status36
- Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
- Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
- A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase 2 Study of WGI-0301 for Advanced HCC
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
- A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Cancer
Stomach cancer
胃癌Led 25 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.
4 hospitals in Changsha for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingShenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT07098026
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingPreliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06543108
Age 18 years to 90 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06760819
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai
- RecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07066657
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou
- RecruitingDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06221748
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led25
- GLIS2 Promotes Epithelial-Mesenchymal Transition and Gastric Cancer Progression by Regulating BGN to Activate the Wnt/β-Catenin Pathway.
- Value of Post-NAC CT-based Node-RADS score for Predicting residual lymph node metastasis and survival outcome of locally advanced gastric cancer.
- Engineering a nano-drug delivery system to regulate m6A modification and enhance immunotherapy in gastric cancer.
- Added value of pretreatment CT-based Node-RADS score for predicting survival outcome of locally advanced gastric cancer: compared with clinical N stage.
- Bone Metastasis Mediates Poor Prognosis in Early-Onset Gastric Cancer: Insights Into Immune Suppression, Coagulopathy, and Inflammation.
- Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [18F]FDG PET/CT.
- Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study.
- Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.
- Prognostic factors and adjuvant chemotherapy efficacy in stage I gastric cancer patients: a retrospective analysis.
- RNA helicase DDX5-induced circPHF14 promotes gastric cancer cell progression.
- Effect of tumor exosome-derived Lnc RNA HOTAIR on the growth and metastasis of gastric cancer.
- Classification of precancerous lesions based on fusion of multiple hierarchical features.
- Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-center study.
- Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma.
- YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells.
- Association among prognostic nutritional index, post-operative infection and prognosis of stage II/III gastric cancer patients following radical gastrectomy.
- Inhibition MNK-eIF4E-β-catenin preferentially sensitizes gastric cancer to chemotherapy.
- Kinesin family member 2A links with advanced tumor stage, reduced chemosensitivity and worse prognosis in gastric cancer.
- EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.
- hsa_circ_0067514 suppresses gastric cancer progression and glycolysis via miR-654-3p/LATS2 axis.
- A novobiocin derivative, XN4, triggers ferroptosis in gastric cancer cells via the activation of NOX4.
- Association Among Blood Transfusion, Postoperative Infectious Complications, and Cancer-Specific Survival in Patients with Stage II/III Gastric Cancer After Radical Gastrectomy: Emphasizing Benefit from Adjuvant Chemotherapy.
- ASO Author Reflections: Association Between Perioperative Blood Transfusion, Infections, and Prognosis of Stage II/III Gastric Cancer Patients.
- The effects and mechanism of α-mangostin on chemosensitivity of gastric cancer cells.
- The effect of Helicobacter pylori eradication on prognosis of postoperative early gastric cancer: a multicenter study.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status30
- Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
- Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
- Procalcitonin to Predict Infection After Gastrectomy for Gastric Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
- A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Changsha for chordoma84 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 8 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Changsha for osteosarcoma570 hospitals in China for osteosarcoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05830123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Identification of EMT-related subtype and a 9 genes signature predicts the prognosis in osteosarcoma.
- COPS5 regulates osteosarcoma progression by upregulating KHSRP to promote Per2 mRNA decay.
- Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis.
- The Eph/Ephrin system in primary bone tumor and bone cancer pain.
- FDG PET/CT of Primary Ewing Sarcoma of the Peritoneum.
- MIR205 host gene (MIR205HG) drives osteosarcoma metastasis via regulating the microRNA 2114-3p (miR-2114-3p)/twist family bHLH transcription factor 2 (TWIST2) axis.
- LncRNA HOTTIP facilitates cell proliferation, invasion, and migration in osteosarcoma by interaction with PTBP1 to promote KHSRP level.
- 3D printing guide plate for accurate hemicortical bone tumor resection in metaphysis of distal femoral: a technical note.
Earlier papers (2016–2020)1
Cancer
Ewing sarcoma
尤文肉瘤Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Changsha for Ewing sarcoma134 hospitals in China for Ewing sarcoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06926283
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Hangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Multiple myeloma
多发性骨髓瘤Led no English-language PubMed papers on multiple myeloma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changsha for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Study of BEBT-908 in Subjects With Advanced Hematological Tumors
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Changsha for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Changsha for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
湖南省肿瘤医院
Hunan Cancer Hospital
长沙
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
Hunan Provincial Tumor Hospital; Graduate Collaborative Training Base of Hunan Cancer Hospital; Hunan Provincial Cancer Hospital; Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya; and Hunan Cancer Hospital; Graduates Collaborative Training Base of Hunan Cancer Hospital; Hunan Cancer Hospital of Central South University; Hunan Cancer Hospital of Xiangya School